There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...

I offered some tips to help reboot your sleep health. That list still contains my top tips. But this year, I want to add to ...

Ozempic, inflation and the Trump presidency will likely dictate food waste trends in the US in 2025, according to non-profit ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for weight loss, and major food conglomerates are trying to cater to their ...